Abstract：
UNASSIGNED: Currently, cancer immunotherapy is widely used as a groundbreaking method that can completely cure advanced cancers. However, this new immunotherapy has the challenge of low patient response, which is often due to many patients\' tumors having an immunosuppressive environment, known as cold tumors.
UNASSIGNED: This review aims to introduce various nanomedicine-derived combinational cancer immunotherapy that can transform cold tumor into hot tumors. Initially, we discuss new technologies for combinational immunotherapy based on multifunctional nanomedicines that can deliver combinational immunogenic cell death (ICD) inducers, immune checkpoint blockades (ICBs) and immune modulators (IMs) to targeted tumor tissues at the same time. Ultimately, we highlight how multifunctional nanomedicines for combinational cancer immunotherapy can be used to transform cold tumor into hot tumors against advanced cancers.
UNASSIGNED: Nanomedicine-derived combinational cancer immunotherapy for delivering multiple ICD inducers, ICBs, and IMs at the same time is recognized as a new potential technology that can activate tumor immunity and simultaneously increase the therapeutic efficacy of immune cells that can transform effectively the cold tumors into hot tumors. Finally, nanomedicine-derived combinational cancer immunotherapy can solve the serious problems of low therapeutic efficacy that occurs when treating single drug or simple combinational drugs in cancer immunotherapy.
UNASSIGNED: This review aims to introduce various nanomedicine-derived combinational cancer immunotherapy that can transform cold tumor into hot tumors. Initially, we discuss new technologies for combinational immunotherapy based on multifunctional nanomedicines that can deliver combinational immunogenic cell death (ICD) inducers, immune checkpoint blockades (ICBs) and immune modulators (IMs) to targeted tumor tissues at the same time. Ultimately, we highlight how multifunctional nanomedicines for combinational cancer immunotherapy can be used to transform cold tumor into hot tumors against advanced cancers.
UNASSIGNED: Nanomedicine-derived combinational cancer immunotherapy for delivering multiple ICD inducers, ICBs, and IMs at the same time is recognized as a new potential technology that can activate tumor immunity and simultaneously increase the therapeutic efficacy of immune cells that can transform effectively the cold tumors into hot tumors. Finally, nanomedicine-derived combinational cancer immunotherapy can solve the serious problems of low therapeutic efficacy that occurs when treating single drug or simple combinational drugs in cancer immunotherapy.
摘要：
■目前，癌症免疫疗法被广泛用作可以完全治愈晚期癌症的开创性方法。然而,这种新的免疫疗法具有低患者反应的挑战，这通常是由于许多患者的肿瘤具有免疫抑制环境，被称为冷肿瘤。
■这篇综述旨在介绍各种纳米医学衍生的组合癌症免疫治疗，这些免疫治疗可将冷肿瘤转化为热肿瘤。最初，我们讨论了基于多功能纳米药物的组合免疫疗法的新技术，该技术可以提供组合免疫原性细胞死亡（ICD）诱导物，免疫检查点阻断(ICBs)和免疫调节剂(IMs)同时靶向肿瘤组织。最终,我们重点介绍了用于联合癌症免疫疗法的多功能纳米药物如何用于将冷肿瘤转化为热肿瘤以对抗晚期癌症。
■纳米医学衍生的联合癌症免疫疗法，用于提供多种ICD诱导剂，ICB,与IMs同时被认为是一种新的潜在技术，可以激活肿瘤免疫，同时增加免疫细胞的治疗功效，可以有效地将冷肿瘤转化为热肿瘤。最后,纳米医学衍生的组合癌症免疫治疗可以解决癌症免疫治疗中治疗单一药物或简单组合药物时出现的低疗效的严重问题。
■这篇综述旨在介绍各种纳米医学衍生的组合癌症免疫治疗，这些免疫治疗可将冷肿瘤转化为热肿瘤。最初，我们讨论了基于多功能纳米药物的组合免疫疗法的新技术，该技术可以提供组合免疫原性细胞死亡（ICD）诱导物，免疫检查点阻断(ICBs)和免疫调节剂(IMs)同时靶向肿瘤组织。最终,我们重点介绍了用于联合癌症免疫疗法的多功能纳米药物如何用于将冷肿瘤转化为热肿瘤以对抗晚期癌症。
■纳米医学衍生的联合癌症免疫疗法，用于提供多种ICD诱导剂，ICB,与IMs同时被认为是一种新的潜在技术，可以激活肿瘤免疫，同时增加免疫细胞的治疗功效，可以有效地将冷肿瘤转化为热肿瘤。最后,纳米医学衍生的组合癌症免疫治疗可以解决癌症免疫治疗中治疗单一药物或简单组合药物时出现的低疗效的严重问题。
